Compugen Ltd. Stock News

HOLON, Israel , March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025: H.C.

Compugen Ltd. (NASDAQ:CGEN ) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Karina Rabayeva – Truist Securities Daina Graybosch - Leeri...

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025 The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previo...

HOLON, ISRAEL  , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, Miami Beach, Florida, on Tuesday, March 11, 2025 at 8:00 AM ET.

Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology and immune regulation Leveraging Compugen's computational analytical tools uncovered high consistency in single-cell expression levels across Ultima's UG 100 sequencing platform, offering a potential...

HOLON, Israel , Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open.

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in cash and milestone payments from Gilead and AstraZeneca, Compugen has a solid financial runway extending into 2027. Compugen's pipeline, including COM701 and COM503, aims to transform tumor responsiveness...

HOLON, Israel , Feb. 4, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference which will take place virtually on February 11, 2025 at 8am ET.